Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, ...

Gliomas account for almost half of all pediatric central nervous system tumors; among these, the BRAF V600E mutation is common in low-grade tumors and is predictive of a poor response to chemotherapy.

In this second installment of MedPage Today's virtual roundtable series on pediatric low-grade glioma, moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, is joined once ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months ...

A collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the treatment of BRAF mutated low-grade paediatric ...

A recent phase 2 trial revealed that the combination of Tafinlar and Mekinist benefitted children with BRAF-mutated low-grade gliomas. A recent phase 2 trial revealed survival and side effect ...

If approved, Ojemda (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, ...